Evidence map›Paper›PMID 41005193›Full record

ArticleEuropean journal of medicinal chemistry2026

(N)-Methanocarba-adenosines as monoamine transporter allosteric inhibitors: Extended N

Dilip K Tosh, Matteo Pavan, Laura B Kozell, Amy J Eshleman, Jennifer L Schmachtenberg, Katherine M Wolfrum, William E Schutzer, Atheir I Abbas, Kenneth A Jacobson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dilip K ToshMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Matteo PavanMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Laura B KozellVA Portland Health Care System, Research Service (R&D-22), and Departments of Psychiatry and Behavioral Neuroscience, Oregon Health and Science Univ., Portland, OR, 97239, USA.
Amy J EshlemanVA Portland Health Care System, Research Service (R&D-22), and Departments of Psychiatry and Behavioral Neuroscience, Oregon Health and Science Univ., Portland, OR, 97239, USA.
Jennifer L SchmachtenbergVA Portland Health Care System, Research Service (R&D-22), and Departments of Psychiatry and Behavioral Neuroscience, Oregon Health and Science Univ., Portland, OR, 97239, USA.
Katherine M WolfrumVA Portland Health Care System, Research Service (R&D-22), and Departments of Psychiatry and Behavioral Neuroscience, Oregon Health and Science Univ., Portland, OR, 97239, USA.
William E SchutzerVA Portland Health Care System, Research Service (R&D-22), and Departments of Psychiatry and Behavioral Neuroscience, Oregon Health and Science Univ., Portland, OR, 97239, USA.
Atheir I AbbasVA Portland Health Care System, Research Service (R&D-22), and Departments of Psychiatry and Behavioral Neuroscience, Oregon Health and Science Univ., Portland, OR, 97239, USA.
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: kennethj@niddk.nih.gov.

Funding

Development of Drugs Acting at Adenosine ReceptorsZIADK031117 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$776k
Development of Drugs Acting at Ion ChannelsZIADK031127 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$388k
Intramural NIH HHS Z01 DK031127Intramural NIH HHS ZIA DK031117Intramural NIH HHS ZIA DK031127
6 · The paper itself

Abstract

A human dopamine transporter (DAT) cryo-EM structure was recently reported, as stabilized by an allosteric inhibitor, i.e. rigid nucleoside MRS7292 1, a tropane orthosteric inhibitor and Zn

Indexed as

AdenosineDopamine Plasma Membrane Transport ProteinsNorepinephrine Plasma Membrane Transport ProteinsSerotonin Plasma Membrane Transport ProteinsAllosteric RegulationDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipAdenosineDopamine Plasma Membrane Transport ProteinsNorepinephrine Plasma Membrane Transport ProteinsSerotonin Plasma Membrane Transport ProteinsDopamineMonoaminesNucleosidesStructure activity relationshipTransporter

Identifiers

PMID41005193
PMCPMC12684230

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.